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Hospital, Helsinki, FinlandObjective: High heparin doses during cardiopulmonary bypass (CPB) have been suggested to reduce thrombin activation and consumption coa-
gulopathy and consequently bleeding complications. The authors investigated the effect of a high heparin dose during CPB on point-of-care
measurements of coagulation. The authors hypothesized that during CPB a high heparin dose compared with a lower heparin dose would reduce
thrombin generation and platelet activation and tested whether this would be reflected in the results of rotational thromboelastometry (TEM) and
platelet aggregation, measured with multiple electrode aggregometry (MEA).
Design: Prospective, randomized, controlled, open single-center study.
Setting: University teaching hospital.
Participants: Sixty-three consecutive patients undergoing elective coronary artery bypass grafting with CPB were enrolled.
Interventions: Patients were randomly assigned to receive either a high (600 IU/kg, n = 32) or a low (300 IU/kg, n = 31) initial dose of heparin.
Target levels of activated clotting time during CPB were >600 seconds in the high heparin dose group and >400 seconds in the low heparin
dose group.
Measurements and Main Results: Blood samples were collected (1) preoperatively after induction of anesthesia, (2) 10 minutes after aortic
declamping, (3) 30 minutes after protamine administration, and (4) 3 hours after protamine administration. TEM and MEA were then measured.
There was no difference in blood loss up to 18 hours postoperatively (median 735 mL for high dose v 610 mL for low dose; p < 0.056) or trans-
fusions between the groups. Total median heparin dose (54,300 IU v 27,000 IU; p = 0.001) and median antifactor Xa levels during CPB
(9.38 U/mL v 5.04 U/mL; p = 0.001) were greater in the high than in the low heparin dose group. However, neither TEM nor MEA results dif-
fered significantly between the groups.
Conclusions: Compared with a lower dose of heparin during CPB, a high dose of heparin had little effect on the point-of-care measurements of
hemostasis, TEM, and MEA. Based on the similarity of platelet and coagulation activity assessments, the higher heparin dose does not appear to
offer benefit during CPB.
 2020 Elsevier Inc. All rights reserved.
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sevier Inc. All rights reserved.HEPARIN is the drug of choice for the mandatory anticoa-
gulation during cardiopulmonary bypass (CPB), but the opti-
mal heparin dose during CPB is not known. High heparin
doses have been suggested to reduce thrombin activation and
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dency.1 Previously, heparin dosing based on an automated
heparin dose-response assay resulted in higher heparin doses
during CPB but fewer transfusions.2 Higher heparin doses dur-
ing CPB also have been shown to reduce activation of coagula-
tion during CPB, as evidenced by lower levels of biomarkers
of thrombin generation and fibrinolysis.3,4
The effects of heparin on platelets are not straightforward.
Heparin may activate platelets via glycoprotein IIb/IIIa and
immunologic mechanisms.5 Platelet factor 4 (PF4) released dur-
ing platelet activation, in turn, can neutralize heparin effects and
inhibits megakaryopoiesis.6 Overall, high heparin doses might
have detrimental effects on sustaining hemostasis. Heparin has
profibrinolytic activity,7,8 it impairs von Willebrand fac-
tordependent platelet functions,9 and heparin-induced throm-
bin inhibition may indirectly impair platelet functions. An initial
heparin dose of 600 IU/kg reduces platelet aggregation com-
pared with a dose of 300 IU/kg.10 Impairment of platelet func-
tion could be detrimental because a number of patients
undergoing cardiac surgery also are undergoing strong adjunct
antiplatelet and novel anticoagulant therapies.
Conventional coagulation tests have been shown to be insuffi-
cient to detect hyperfibrinolysis and platelet dysfunction, the
most important causes of nonsurgical bleeding episodes after
CPB.11-13 At present, several point-of-care (POC) tests of hemo-
stasis and platelet function are available to improve and acceler-
ate coagulation monitoring. Two commonly used POC tests are
rotational thromboelastometry (TEM) and multiple electrode
aggregometry (MEA). There is evidence that the use of POC
tests to guide transfusion management in cardiac surgery may
reduce blood loss, transfusion requirements, and morbidity,14-17
although contradicting results also have been published.18
Maintaining high heparin concentrations during CPB results
in reduced coagulation activation and may correlate with
reduced transfusion requirements.19 Therefore, the authors per-
formed a randomized trial (EudraCT number 2012-000449-11)
comparing a high (600 IU/kg, target activated clotting time
[ACT] during CPB >600 s) and low (300 IU/kg, target ACT
during CPB >400 s) dose of heparin in patients undergoing
CPB for coronary artery bypass grafting (CABG). The present
investigation is a substudy of a larger ongoing randomized trial,
which aims to recruit 200 patients. The present study’s aim was
to compare the effects of heparin dosing on TEM and MEA
with their multiple assessments using distinct activators.Patients and Methods
Patients
Sixty-three consecutive patients undergoing elective CABG
with CPB were enrolled into this prospective, randomized,
controlled, single-center study between February 3, 2012, and
March 11, 2015. The Ethics Committee of the Hospital District
of Helsinki and Uusimaa, Helsinki, Finland, approved the
study. All patients gave written informed consent to participate
in the study. Exclusion criteria were as follows: urgent sur-
gery; redo surgery; concomitant cardiac surgery in addition toCABG; antiplatelet or anticoagulant medication other than
aspirin; biological diseasemodifying anti-inflammatory
drugs, peroral glucocorticoids; cytostatic drugs, hemoglobin
<12 g/dL; platelet count <130£ 109/L; international normal-
ized ratio >1.2; left ventricular ejection fraction <35%; esti-
mated glomerular filtration rate <50 mL/min; and C-reactive
protein >20 mg/L.
Anesthesia and CPB
Benzodiazepines (diazepam, 5-10 mg, or lorazepam, 1-3 mg)
were administered orally as premedication. Beta-blockers, cal-
cium channel blockers, and long-acting nitroglycerin were given
on the morning of the surgery, but other cardiovascular medica-
tions were discontinued. A peripheral arterial line was posi-
tioned before induction of anesthesia. General anesthesia was
induced with propofol or etomidate, fentanyl or sufentanil, and
rocuronium and was maintained with sevoflurane, fentanyl or
sufentanil, and rocuronium. After induction of anesthesia and
tracheal intubation, a central venous catheter was placed in the
internal jugular vein.
CPB was performed using a nonpulsatile pump (St€ockert S5,
Munich, Germany), a membrane oxygenator (Dideco Avant;
Sorin Group, Mirandola, Italy), and a phosphorylcholine-
coated circuit (Phisio; Sorin Group). The CPB circuit was
primed with 1,500 mL of Ringer’s solution and 5,000 IU of
heparin. Oxygen/air mixture was set to achieve a 70% oxygen
concentration in the oxygenator. During perfusion, target val-
ues were as follows: perfusion flow>2.4 L/min/m2, mean arte-
rial pressure 70 mmHg, mixed venous oxygen saturation
>70%, and arterial blood partial pressure of carbon dioxide
4.5 to 5.5 kPa. Mild hypothermia was induced during CPB,
with a target nasopharyngeal temperature of 34˚C. Postopera-
tively, the mean arterial pressure was kept 70 mmHg. Vol-
ume status was optimized with Ringer’s solution, 6%
hydroxyethyl starch solution, or 4% albumin solution. Norepi-
nephrine and epinephrine infusions were used, if needed.
Study Intervention
Because of the distinctly different ACT values between the
study groups, the study was inevitably unblinded by nature in
the operating room. The personnel in the intensive care unit
and the laboratory were blinded to the patient allocation into
the treatment groups. Patients were randomly assigned imme-
diately before surgery using a lottery box. Before cannulation
for CPB, 300 IU/kg (low-dose group) or 600 IU/kg (high-dose
group) of unfractionated heparin (Leo Pharmaceutical Prod-
ucts, Denmark) was administered intravenously as an initial
bolus dose. In both study groups, 5,000 IU of heparin was
added to the priming volume of the CPB circuit.
Kaolin-ACT (Medtronic, Minneapolis, MN) was measured
before the onset of CPB, every 20 minutes during CPB, and 3
minutes after each additional heparin bolus. The target ACT
was >400 seconds in the low-dose group and >600 seconds in
the high-dose group. The additional bolus dose of heparin was
60 IU/kg in both treatment groups. In both treatment groups,
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IU of the initial doses of heparin. Of the total dose of prot-
amine, two-thirds was given within 10 minutes after CPB. The
rest of the protamine dose was infused within 30 minutes at
the same time as the blood recovered from the CPB circuit
was transfused to the patient. Heparinase-ACT was measured
after protamine was administered if the ACT was greater than
the ACT before heparin administration to detect any possible
residual heparin effect. If the heparinase-ACT was >10% than
the conventional ACT, 50 mg of protamine was administered
to both treatment groups.
In both study groups, 25 mg/kg of tranexamic acid was
administered intravenously before the surgical incision, and a
second dose of 10 mg/kg was administered after the main dose
of protamine. During CPB, red blood cells were transfused if
hemoglobin was <60 g/L. The patients were followed-up for
18 postoperative hours. During the first 4 postoperative hours,
platelet count, prothrombin time, and heparinase-ACT were
measured if the chest tube drainage exceeded 100 mL/15
minutes or 200 mL/h. Thereafter, the limit was 100 mL/h.
Transfusion triggers were as follows: hemoglobin <80 g/L for
red blood cells, platelet count <100£ 109/L for platelets, and
international normalized ratio >1.5 for solvent-detergent-
treated standardized plasma (Octaplas; Octapharma AG,
Lachen, Switzerland). When the transfusion trigger was met, 1
to 2 U of red blood cells or 8 U of platelets or 15 mL/kg of
plasma were transfused.Blood Samples and Analyses
Blood samples were drawn from the peripheral arterial cath-
eter (off-CPB) or the arterial line of the CPB circuit (on-CPB)
at the following time points: (1) preoperatively after induction
of anesthesia, (2) 10 minutes after aortic declamping, (3)
30 minutes after protamine administration, and (4) 3 hours
after protamine administration.
For whole blood TEM analysis (ROTEM; Pentapharm Co,
Munich, Germany), blood samples were collected into tubes
containing 3.2% sodium citrate (BD Vacutainer; Verum Diag-
nostica GmbH, Munich, Germany). ExTEM and FibTEM
were performed within 2 hours of blood sampling. ExTEM
clotting time (CT), ExTEM maximum clot firmness (MCF),
and FibTEM MCF were a priori chosen as the outcome meas-
ures. TEM analysis was performed from samples of 29 of
31 patients in the low heparin dose group and of 30 of 32
patients in the high heparin dose group. In both groups, sam-
ples from 2 patients were deleted owing to technical reasons.
Samples for MEA analysis (Multiplate; Verum Diagnostica
GmbH, Munich, Germany) were collected into tubes contain-
ing 15 mg/mL of hirudin (Vacutainer; Verum Diagnostica
GmbH). MEA analyses were performed on whole blood after
a resting period of 30 minutes using thrombin-receptor-activat-
ing-peptide (TRAPtest), arachidonic acid (ASPItest), and
adenosine diphosphate (ADPtest) as agonists. MEA analysis
was performed from samples of 29 of 31 patients in the low
heparin dose group and of 31 of 32 patients in the high heparindose group. Samples from the 3 patients were deleted owing to
technical reasons.
Samples for antifactor Xa (anti-FXa) activity in plasma as
the measure of heparin effects were collected into tubes (3.2%
sodium citrate) (BD Vacutainer) on ice and centrifuged
(2,000g/10 min) at +4˚C. Plasma was separated and stored at
80˚C. Plasma anti-FXa activity was determined with a chro-
mogenic assay with standard supplementation concentration of
antithrombin (Berichrom Heparin; Siemens Healthcare Diag-
nostics, Marburg, Germany).
Statistical Analysis
The sample size was calculated with MedCalc for Windows
software, Version 15.0 (MedCalc Software, Ostend, Belgium).
In a previous study, a 24% decrease in intraoperatively mea-
sured mean TEG maximum amplitude was associated with
increased postoperative blood loss.20 In order to be conserva-
tive in the sample size estimation, the sample size calculation
in the present study was based on an expected 15% difference
in FibTEM MCF and ExTEM MCF of the TEM tracing. For
the power calculation, FibTEM MCF (mean 15.4 mm, stan-
dard deviation 3.0 mm) and ExTEM MCF (mean 58.5 mm,
standard deviation 5.0 mm) values of the preoperative Ringer’s
group of the authors’ previous publication were used.21 The
calculation based on FibTEM MCF yielded 28 patients per
group to detect a difference of 8.8 mm (15%) between the
study groups with an a- and -error of 0.05 and 0.2, respec-
tively.21 The study was not powered to detect differences in
postoperative blood loss between the groups.
SPSS software, version 22 (IBM Corp, Armonk, NJ), was
used for statistical analysis. Because logarithmic transforma-
tion failed to normalize skewed distributions and the sample
size was small, nonparametric tests were used. Differences
between the study groups were tested with the Mann-Whitney
U test. Owing to repeated measurements at 4 time points, the
Bonferroni correction was applied, and p values < 0.0125
were considered to be significant. The data are presented as
numbers or as medians and interquartile ranges (IQR).
Results
Study Population
The patient characteristics were comparable between the
study groups (Table 1). There were no differences in comor-
bidities, medications, or preoperative laboratory values
between the study groups (data not shown). No major adverse
events (eg, stroke, myocardial infarction, venous thromboem-
bolism, acute kidney injury or resternotomy) occurred during
the study. The surgical data are presented in Table 2.
Heparin and Protamine Dose
Total heparin dose (median 54,300 [IQR 46,950-62,250] IU
v median 27,000 [IQR 24,420-34,920] IU; p < 0,001) and
anti-FX activity (median 9.3 [IQR 8.3-9.9] U/mL v median 5.1
Table 1






Male/female 29/2 29/3 0.67
Age (y) 64 (57-72) 70 (59-74) 0.36
Weight (kg) 83 (74-93) 88 (77-104) 0.26
Height (cm) 174 (170-180) 176 (170-180) 0.80
NOTE. Data are presented as numbers or median values and interquartile
range.
Fig 1. Antifactor Xa in the low (circles) and high (squares) heparin dose groups.
Anti-FXa, antifactor Xa; T1, preoperatively after induction of anesthesia; T2, 10
minutes after aortic declamping; T3, 30 minutes after protamine administration;
T4, 3 hours after protamine administration.
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the high-dose than in the low-dose group during CPB (Fig 1).
A single additional heparin dose was administered to 17 of 31
(55%) patients in the low heparin dose group and to 4 of 32
(12.5%) patients in the high heparin dose group. As expected,
the total protamine dose needed to neutralize heparin also was
greater in the high heparin dose group (median 544 [IQR 468-
628] mg) than in the low heparin dose group (median 259
[IQR 230-280] mg; p = 0.01).TEM
All median TEM values (Fig 2) at all 4 time points in both
study groups were within the reference ranges reported by the
manufacturer.22 ExTEM CT, ExTEM MCF, and FibTEM
MCF values were comparable in the groups at all time points
measured, except for the ExTEM CT values measured 3 hours
after protamine administration (see Fig 2).MEA
Preoperatively, median values of the MEA ASPItest were
within the reference range in both the high and low heparin
dose groups (Fig 3). During CBP, ASPItest aggregation
responses were impaired compared with preoperative values
and were below the lower limit of the reference range in both
groups. After CPB, at 3 hours after protamine administration,
ASPItest values recovered in both groups but remained belowTable 2






Pre-CPB ACT (s) 131 (123-141) 129 (123-143) 0.78
ACT (s) after
heparin
488 (439-564) 999 (892-999) 0.001
First ACT (s) on
CPB
474 (422-538) 860 (757-999) 0.001
Post-CPB ACT (s) 126 (115-133) 128 (117-140) 0.32
CPB time (min) 97 (75-119) 95 (79-119) 0.90
Cross-clamp time
(min)
70 (51-83) 66 (58-80) 0.84
NOTE. Data are presented as numbers or median values and interquartile
range.
Abbreviations: ACT, activated clotting time; CPB, cardiopulmonary bypass.the lower limit of the reference range in the high heparin dose
group but not in the low heparin dose group. However, the dif-
ferences in the MEA ASPItest values between the groups did
not reach statistical significance at any time points measured
(see Fig 3). Median ADP-triggered aggregation rates of MEA
were within the reference ranges at all 4 time points in both
study groups and did not differ at any time point (see Fig 3).
The median TRAP-induced aggregation did not differ at any
time point between the study groups (see Fig 3).Blood Loss and Transfusions
There was no significant difference in chest tube output dur-
ing the first 18 postoperative hours between the high-dose
(median 735 [IQR 543-830] mL) and the low-dose (median 610
[IQR 510-720] mL) heparin groups (p = 0.056). There was no
significant difference between the study groups in blood product
transfusions up to the follow-up of 18 postoperative hours. One
patient in both groups received 2 U of red blood cells in the
intensive care unit, and 1 patient in the low heparin dose group
received 2 U of platelets after CPB in the surgery room.Discussion
In patients who received either a high or a conventional dose
of heparin during CPB, there were no significant dose-depen-
dent differences in TEM ExTEM CT, ExTEM MCF, or Fib-
TEM MCF values, except for a small difference in ExTEM
CT at 3 hours after protamine administration. Strikingly, all of
the median TEM values studied in citrated blood were within
the normal ranges reported by the manufacturer at all time
points.22 Likewise, platelet aggregation in hirudin-anticoagu-
lated whole blood did not differ between the groups with any
of the aggregation triggers.
There are at least 2 possible explanations for the present
findings. First, the potential differences in hemostasis between
the 2 heparin dose groups may be beyond the detection limit
of TEM and MEA. This question could not be further
addressed specifically in the present study, which focused on
POC measurements in the absence of laboratory-based
Fig 2. ExTEM clotting time, ExTEM maximum clot firmness, and FibTEM
maximum clot firmness in the low (white) and high (hatched) heparin dose
groups. Gray background denotes reference values reported by the manufac-
turer.22 CT, clotting time; MCF, maximum clot firmness; T1, preoperatively
after induction of anesthesia; T2, 10 minutes after aortic declamping;
T, 30 minutes after protamine administration; T4, 3 hours after protamine
administration. *p < 0.05.
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have been previous concerns that TEM and MEA assays are
not sensitive enough during cardiac surgery, during which
strong dual extrinsic and intrinsic pathway activation occursbecause of tissue factor exposure and neutrophil activation with
netosis.23 Furthermore, previously TEM failed to be sensitive
enough to detect low platelet counts or platelet dysfunction in
experimental hemodilution in vitro.24 High heparin concentra-
tions overall (plasma levels of anti-FXa >2-4 IU/mL) have
been reported to alter TEM measurements.25
The second and alternative explanation is that the 2 heparin
doses used in the present study indeed did not result in signifi-
cant differences in hemostasis. In previous publications, the
effect of heparin dosing on hemostasis during CPB was evalu-
ated primarily by measuring biomarkers of thrombin activation
and fibrinolysis. These biomarkers, however, do not directly
reflect whole blood hemostasis. The interpretation of TEM is
not without problems, either. It is an in vitro method with an
unphysiologically high concentration of tissue factor as an ini-
tiator of coagulation. Still, different functional aspects of coag-
ulation can be addressed with TEM. Importantly, application
of validated algorithms of viscoelastometry is related to the
reduced need of blood products in cardiac surgery.16 In the
present study, no differences between the study groups were
observed in either initiation of coagulation or clot firmness.
More specifically, no difference in FibTEM MCF, which was
within the normal reference range in most patients in both
study groups, was detected. This suggests that either a high or
low heparin dose did not lead to significantly lowered fibrino-
gen levels. These results are compatible with the finding that
there was no significant difference in blood loss or transfusions
between the study groups, although the study was underpow-
ered in this respect.
Again, no differences were observed between the high and
low heparin dose groups in MEA platelet aggregation, irre-
spective of the aggregation trigger. Despite this, reduced plate-
let aggregation was detected with the MEA ASPItest during
CPB in both groups. There are several possible explanations
for the latter finding. First, heparin impairs von Willebrand
factordependent platelet function,9 and high doses of heparin
have been shown to inhibit platelet aggregation and reduce
clot strength.26 Heparin also inhibits the formation of throm-
bin, the most potent in vivo platelet activator.27 Very high hep-
arin activity was measured in both treatment groups in the
present study with median anti-FXa activity level during CPB
>9 U/L in the high heparin dose group and >5 U/mL in the
lower dose group. The authors of the present study are not
aware of previous studies comparing platelet aggregation dur-
ing CPB at such high heparin concentrations. The fact that this
difference in heparin concentrations did not translate into a dif-
ference in MEA platelet aggregation between the groups is in
agreement with the present TEM results. As previously stated,
comparable FibTEM MCF between the study groups indicates
that plasma fibrinogen concentration was comparable.
Together with FibTEM data, ExTEM MCF also was compara-
ble, suggesting that platelet engagement in whole blood fibrin
formation did not deviate between the study groups.
In the high heparin dose group, median ASPItest results
remained below the lower limit of the reference range, even
after heparin reversal. It has been previously shown that at high
heparin concentrations (4 U/mL), protamine concentrations,
Fig 3. Multiple electrode aggregometry arachidonic acid test, adenosine
diphosphate test, and thrombin-receptor-activating-peptide test in the low
(white) and high (hatched) heparin dose groups. Gray background denotes ref-
erence values of the local clinical laboratory of the hospital. ADP, adenosine
diphosphate; ASPI, arachidonic acid; MEA, multiple electrode aggregometry;
T1, preoperatively after induction of anesthesia; T2, 10 minutes after aortic
declamping; T3, 30 minutes after protamine administration; T4, 3 hours after
protamine administration; TRAP, thrombin-receptor-activating-peptide test.
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to reverse its antiplatelet effects26 and that the CPB-induced
impairment of platelet aggregation was not reversed at the time
of protamine administration,28 but only after 24 hours afterCPB.29 Furthermore, excess protamine itself can inhibit platelet
functions.30 Therefore, the higher protamine doses in the high
heparin dose group may have affected the results after reversal
of heparin. Indeed, the observed tendency to lower aggregation
responses to arachidonic acid at 3 hours after heparin reversal in
the high heparin dose group may have been influenced by both
residual heparin effect and protamine dosing.
Despite its randomized setting, there are limitations in the
present study. First, the trial was unblinded in the operating
room. This could not be avoided because different heparin
doses resulted in notably different ACT values. In the intensive
care unit, on the other hand, all personnel were blinded with
regard to the study group. Second, platelet counts were not
monitored during surgery because the aim of the study was to
assess the effects of heparin dosing on the POC measurements.
It has been shown that the platelet count decreases during CPB
and reaches a plateau at 2 hours after CPB.31 In the present
study, low platelet counts during the surgery may have
affected the results.32 However, based on the inclusion crite-
rion, preoperative platelet counts were within normal range
and the preoperative and postoperative platelet counts did not
differ between the study groups. Third, AT3 levels were not
measured. As a strength, the study groups differed substan-
tially from each other in terms of the study intervention. Dur-
ing CPB with systemic heparinization, the anti-FXa activity in
the high heparin dose group was >1.5-fold greater than the
activity in the low heparin dose group.Conclusions
In the present randomized clinical trial, the whole blood
POC assays TEM and MEA did not demonstrate significant
differences in either coagulation or platelet function in patients
anticoagulated with a high or standard dose of heparin during
cardiac surgery. Therefore, although the higher dose of
heparin was as safe as the lower dose, regarding POC measure-
ments, it does not seem to offer any benefit.Conflict of Interest
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